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AbstrAct
Breast cancer is still the most frequent cancer diagnosed 
in women aged ≤40 years and the primary cause of death 
in this age group. The management of these patients 
needs a dedicated approach involving a multidisciplinary 
team that takes into account their treatment and 
survivorship issues. The present review aims to provide 
a perspective on the many challenges associated with 
treatment of young women with early breast cancer. 
We will focus on the standard (neo)adjuvant treatment, 
highlighting the paucity of age-specific results about 
the available genomic signatures, the groundbreaking 
landscape of adjuvant endocrine therapy and the relevant 
issue of the fertility preservation.
IntroduCtIon
Breast cancer in young women (defined 
as breast cancer in women aged ≤40 years) 
represents less than 7% of all diagnosed 
breast cancer in developed countries.1 In 
low-income countries, the proportion of cases 
of breast cancer diagnosed among young 
women is higher (up to 20%). These differ-
ences may be due to environmental factors, 
genetic differences or reproductive behav-
iour between different regions.2 3
Even if it can be considered a rare disease, 
breast cancer is the most commonly diag-
nosed malignancy among adult women and 
the primary cause of death in this age group.4 
Breast cancer arising in young women is char-
acterised by a more aggressive behaviour, 
greater proportion of high-grade, triple-neg-
ative and HER2-positive disease, the more 
advanced stage at diagnosis as compared with 
the older counterpart.5
The prognostic value of young age varies by 
breast cancer subtypes: young age does not 
seem to be a predictor of worse outcome in 
patients with triple-negative and HER2-pos-
itive subtypes, while it has a substantial 
prognostic role in luminal tumours.6 This 
divergence may reflect differences in tumour 
biology, inappropriate treatment (ie, the 
absence of ovarian suppression as part of the 
endocrine treatment) and lower therapeutic 
adherence and persistence to endocrine 
therapies.6
AdjuvAnt systemIC treAtment
International guidelines for the manage-
ment of breast cancer in young women state 
that adjuvant systemic treatment decisions 
in this setting should be similar to those in 
older patients. Specifically, treatment deci-
sion-making should be mainly driven by 
the biological characteristics of the tumour 
(including tumour size, nodal involvement, 
grade, proliferation, hormonal receptor 
status and HER-2 expression), patient's pref-
erences and comorbidities; importantly, 
young age itself should not be considered a 
reason to use more aggressive treatments.7
(neo)AdjuvAnt ChemotherApy
The optimal adjuvant chemotherapy regimen 
specifically for young women is not currently 
defined. Yet, the standard regimen is the 
combination of an anthracycline, alkylating 
agent and taxane similar to that in older 
patient candidates to adjuvant chemotherapy 
for early breast cancer.7
Dose-dense chemotherapy is a mainstay 
adjuvant treatment for high-risk patients 
breast cancer.8 To specifically investigate the 
role of the dose-dense schedule in young 
patients with breast cancer, a pooled analysis 
restricted to premenopausal women enrolled 
in two adjuvant chemotherapy trials has been 
recently performed.9 In high-risk premeno-
pausal patients with breast cancer, the use 
of a dose-dense regimen was associated with 
better overall survival (HR 0.71, 95% CI 0.54 
to 0.95, p=0.021), as compared with standard 
duration regimen, without further risk of 
chemotherapy-induced amenorrhoea.9 Also 
the preliminary results of the meta-analysis 
based on individual patient data conducted 
by the Early Breast Cancer Trialists Collabo-
rative Group confirmed that increasing the 
dose density of adjuvant chemotherapy led to 
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significant improvement in breast cancer recurrence and 
mortality, regardless of patients’ age.10
In the light of the above results, dose-dense anthracy-
cline and taxane-based regimen should be regarded as 
the preferred option in high-risk premenopausal patients 
with breast cancer who are candidates to receive chemo-
therapy. Another potential added benefit of a shorter 
chemotherapy duration in young patients may be the 
quicker recovery from the negative side effects of the 
treatment (such as the alopecia) with positive impact also 
on their return to their job.9
The role of neoadjuvant platinum-based chemotherapy 
in patients with triple-negative breast cancer is still contro-
versial. A recent meta-analysis showed that platinum-based 
neoadjuvant chemotherapy significantly increased rates 
of pathological complete response rate from 37.0% to 
52.1% (p<0.001), at the cost of higher toxicity.11 Being 
the triple-negative phenotype more frequent in young 
patients, the addition of a platinum agent to a standard 
neoadjuvant chemotherapy may be considered an appro-
priate approach particularly in this group of women.
Recently, multigene prognostic tests have been devel-
oped to assist clinicians in the process of adjuvant decision, 
in addition to traditional clinical pathological features.7 
The 21-gene recurrence score assay (Oncotype DX) is 
one of the available gene expression signatures able to 
provide prognostic information that can help in identi-
fying the patients with hormone receptor-positive breast 
cancer who may benefit from the addition of chemo-
therapy. In the TailorX study, the use of chemotherapy 
in the younger women with an intermediate recurrence 
score of 16–25 (46% of patients in this age group) was 
associated with improved survival.12 However, only 13% of 
these women received ovarian function suppression that 
is currently considered a key part of endocrine therapy 
in premenopausal patients at higher risk of disease 
recurrence. Further research on this topic is required 
to better clarify the potential role of genomic signatures 
to add prognostic information in young patients to help 
discussing the additional benefit of chemotherapy in this 
setting.
AdjuvAnt endoCrIne therApy
The choice of the most appropriate adjuvant endocrine 
treatment is of particular importance among premeno-
pausal women considering the negative prognostic value 
of young age in this tumour subtype and the many options 
that are now available.
Recently, the panorama of adjuvant endocrine therapy for 
premenopausal patients has dramatically changed and the 
choice of the best approach has become quite complex.13
The updated results of the Tamoxifen and Exemestane 
trial (TEXT) and Suppression of Ovarian Function Trial 
(SOFT) have enriched the landscape of adjuvant endo-
crine therapy for premenopausal patients with breast 
cancer.14
The SOFT trial randomly assigned 3066 premeno-
pausal women to receive 5 years of tamoxifen alone, 
ovarian function suppression combined with tamoxifen 
or exemestane. After a median follow-up of 8 years, the 
addition of ovarian function suppression (OFS) to tamox-
ifen significantly improved disease-free survival (HR 0.76, 
95% CI 0.60 to 0.97), which translated into an absolute 
difference of 4.2 percentage points. The absolute bene-
fits were larger in the group of patients who remained 
premenopausal after previous chemotherapy, with higher 
risk clinical pathological features and higher risk of 
relapse.14
In the joint analysis of the SOFT and TEXT, 4690 
premenopausal patients were randomised to receive OFS 
combined with tamoxifen or exemestane. At a median 
follow-up of 9 years, the treatment with exemestane plus 
OFS was associated to higher rates of disease-free survival 
(86.8% vs 82.8%, 4.0% absolute benefit) and freedom 
from distant recurrence (91.8% vs 89.7%, 2.1% absolute 
benefit), compared with tamoxifen plus ovarian func-
tion suppression. Based on the available evidence on 
this regard, oestrogen receptor-positive/HER2-negative 
premenopausal patients with early breast cancer consid-
ered at high risk of relapse, and treated with adjuvant 
chemotherapy, derived greater benefit to the combina-
tion of exemestane plus OFS, being the suitable candi-
dates for this treatment strategy.14 On the other hand, 
tamoxifen alone or associated with OFS is an option for 
young women with less aggressive characteristics, and for 
those who cannot tolerate the side effects of aromatase 
inhibitors.
Up to 20% of the young patients stopped therapies 
prematurely, especially those younger than 35 years, due 
to the related adverse events.15 Since early discontinua-
tion of endocrine therapy is associated with worse prog-
nosis, patients should be aware of the toxicities of the 
different therapies and appropriate supportive measures 
are needed to increase the compliance to long-term 
endocrine therapy.16
The substudy SOFT-Estrogen Substudy (EST) showed 
that up to 20% of women treated with exemestane plus 
OFS did not experience a complete ovarian suppres-
sion.17 Therefore, in young patients on exemestane a 
monitoring of oestradiol levels and the possible onset of 
premenopausal symptoms is recommended (ie, vaginal 
bleeding): in case of inadequate ovarian suppression, 
patients should be shifted to tamoxifen in addition to 
OFS.
The best timing of beginning pharmacological OFS in 
case of adjuvant chemotherapy is not still clearly defined, 
although a concomitant administration has the additional 
capability to preserve ovarian function without negative 
impact on the long-term outcome.18 19
To date, no data are available on extended therapy 
beyond 5 years for patients who underwent exemestane 
combined with OFS.
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preservAtIon of fertIlIty
Many young women have not completed the family plan-
ning at the time of breast cancer diagnosis.20 21 Taking 
also into account the improved survival, oncologists must 
now consider also the long-term side effects associated 
with the use of the proposed anticancer treatments. Inter-
national guidelines recommend that all young patients 
should be properly and promptly counselled about the 
impact of anticancer treatment on their fertility and the 
available techniques for fertility preservation.7 22 Failure 
to address these vulnerable topics can negatively influ-
ence the compliance to the proposed anticancer thera-
pies, potentially negatively affecting prognosis.20
Nowadays, different techniques for fertility preservation 
in these patients are available: embryo and oocyte cryopres-
ervation are the main options to be proposed.23 The role of 
temporary ovarian suppression with gonadotropin-releasing 
hormone agonists (GnRHa) during chemotherapy has 
been recently evaluated in a meta-analysis of individual data 
as a strategy for ovarian function and fertility preservation.19 
Concomitant administration of GnRHa and chemotherapy 
was associated with a significant reduced risk of developing 
iatrogenic premature ovarian insufficiency (adjusted OR 
0.38; 95% CI 0.26 to 0.57) and significantly higher chances 
of having a post-treatment pregnancy (incidence rate ratio 
1.83; 95% CI 1.06 to 3.15). No detrimental impact on long-
term outcomes was observed.19 Therefore, GnRHa during 
chemotherapy can now be offered to premenopausal 
patient candidates to receive chemotherapy and interested 
in preserving ovarian function and potential fertility.7 23
The issue of the fertility preservation is becoming more 
relevant also for the recent findings that pregnancy after 
breast cancer did not affect prognosis and should not 
be discouraged including among women with hormone 
receptor-positive disease.24
ConClusIons
Managing breast cancer in young women has become 
more complex thanks to the availability of a growing 
among of data in this field. The management of these 
patients needs a dedicated approach involving a multi-
disciplinary team that takes into account their treatment 
and survivorship issues.25
Prospective trials specifically focused to breast cancer in 
young women are needed to further improve the manage-
ment of these patients.
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